A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

BACKGROUND: Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical studies demonstrated that indoximod combined with chemotherapy was synergistic in a mouse model of breast cancer. A phase I 3+3 trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Hatem H., Jackson, Erica, Neuger, Tony, Dees, E. Claire, Harvey, R. Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N., Link, Charles, Sullivan, Daniel M., Antonia, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226672/
https://www.ncbi.nlm.nih.gov/pubmed/25327557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226672/
https://www.ncbi.nlm.nih.gov/pubmed/25327557

Ejemplares similares